We have previously shown correlation between baseline CSF-NfL and worsening ofdisability defined by EDSS after five years of follow-up11 This study further strengthens the use of CSF-NfL as a prognostic biomarkerfor clinical and radiological disease worsening in newly diagnosed MS. This evidence concerns the gene NEFL and myeloid sarcoma.